Combining oncolytic virus with FDA approved pharmacological agents for cancer therapy

References

• Jessy T. Immunity over inability: the spontaneous regression of cancer. J Nat Sci Biol Med. 2011;2(1):43–49.
   PubMedGoogle Scholar
• Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther. 2007;15(4):651–659.
   PubMed Web of Science ®Google Scholar
• Chen FM, Liu X. Advancing biomaterials of human origin for tissue engineering. Prog Polym Sci. 2016;53:86–168.
   PubMed Web of Science ®Google Scholar
• Martuza RL, Malick A, Markert J, et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science. 1991;252(5007):854–856.
   PubMed Web of Science ®Google Scholar
• Kiyokawa J, Wakimoto H. Preclinical and clinical development of oncolytic adenovirus for the treatment of malignant glioma. Oncolytic Virother. 2019;8:27–37.
   PubMed Web of Science ®Google Scholar
• Mell LK, Brumund KT, Daniels GA, et al. Phase I trial of intravenous oncolytic vaccinia virus (GL-ONC1) with cisplatin and radiotherapy in patients with locoregionally advanced head and neck carcinoma. Clin Cancer Res. 2017;23(19):5696–5702.
   PubMed Web of Science ®Google Scholar
• Msaouel P, Opyrchal M, Dispenzieri A, et al. Clinical trials with oncolytic measles virus: current status and future prospects. Curr Cancer Drug Targets. 2018;18(2):177–187.
   PubMed Web of Science ®Google Scholar
• Geletneky K, Hajda J, Angelova AL, et al. Oncolytic H-1 parvovirus shows safety and signs of immunogenic activity in a first phase I/IIa glioblastoma trial. Mol Ther. 2017;25(12):2620–2634.
   PubMed Web of Science ®Google Scholar
• Gromeier M, Nair SK. Recombinant poliovirus for cancer immunotherapy. Annu Rev Med. 2018;69:289–299.
   PubMed Web of Science ®Google Scholar
• Pol JG, Zhang L, Bridle BW, et al. Maraba virus as a potent oncolytic vaccine vector. Mol Ther. 2014;22(2):420–429.
   PubMed Web of Science ®Google Scholar
• Le Boeuf F, Gebremeskel S, McMullen N, et al. Reovirus FAST protein enhances vesicular stomatitis virus oncolytic virotherapy in primary and metastatic tumor models. Mol Ther Oncolytics. 2017;6:80–89.
   PubMed Web of Science ®Google Scholar
• Samson A, Bentham MJ, Scott K, et al. Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer. Gut. 2018;67(3):562–573.
   PubMed Web of Science ®Google Scholar
• Deng H, Liu H, de Silva T, et al. Coxsackievirus type B3 is a potent oncolytic virus against KRAS-mutant lung adenocarcinoma. Mol Ther Oncolytics. 2019;14:266–278.
   PubMed Web of Science ®Google Scholar
• Liu H, Xue YC, Deng H, et al. MicroRNA modification of Coxsackievirus B3 decreases its toxicity, while retaining oncolytic potency against lung cancer. Mol Ther Oncolytics. 2020;16:207–218.
   PubMed Web of Science ®Google Scholar
• Relph K, Annels N, Smith C, et al. Oncolytic immunotherapy for bladder cancer using Coxsackie A21 virus: using a bladder tumor precision-cut slice model system to assess viral efficacy. Methods Mol Biol. 2020;2058:249–259.
   PubMedGoogle Scholar
• Hastie E, Grdzelishvili VZ. Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. J Gen Virol. 2012;93(Pt 12):2529–2545.
   PubMed Web of Science ®Google Scholar
• Shao X, Wang X, Guo X, et al. STAT3 contributes to oncolytic newcastle disease virus-induced immunogenic cell death in melanoma cells. Front Oncol. 2019;9:436.
   PubMed Web of Science ®Google Scholar
• Schirrmacher V, van Gool S, Stuecker W. Breaking therapy resistance: an update on oncolytic newcastle disease virus for improvements of cancer therapy. Biomedicines. 2019;7(3):66.
   PubMed Web of Science ®Google Scholar
• McCarthy C, Jayawardena N, Burga LN, et al. Developing picornaviruses for cancer therapy. Cancers (Basel). 2019;11(5):685.
   PubMed Web of Science ®Google Scholar
• Greig SL. Talimogene Laherparepvec: first global approval. Drugs. 2016;76(1):147–154.
   PubMed Web of Science ®Google Scholar
• Siu LL, Ivy SP, Dixon EL, et al. Challenges and opportunities in adapting clinical trial design for immunotherapies. Clin Cancer Res. 2017;23(17):4950–4958.
   PubMed Web of Science ®Google Scholar
• Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol. 2010;28(24):3838–3843.
   PubMed Web of Science ®Google Scholar
• Jahan N, Lee JM, Shah K, et al. Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus. Int J Cancer. 2017;141(8):1671–1681.
   PubMed Web of Science ®Google Scholar
• Kanai R, Rabkin SD, Yip S, et al. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells. J Natl Cancer Inst. 2012;104(1):42–55.
   PubMedGoogle Scholar
• Gomez-Gutierrez JG, Nitz J, Sharma R, et al. Combined therapy of oncolytic adenovirus and temozolomide enhances lung cancer virotherapy in vitro and in vivo. Virology. 2016;487:249–259.
   PubMed Web of Science ®Google Scholar
• Jiang G, Sun C, Li R-H, et al. Enhanced antitumor efficacy of a novel oncolytic adenovirus combined with temozolomide in the treatment of melanoma in vivo. J Cancer Res Clin Oncol. 2015;141(1):75–85.
   PubMed Web of Science ®Google Scholar
• Mantwill K, Naumann U, Seznec J, et al. YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells. J Transl Med. 2013;11:216.
   PubMed Web of Science ®Google Scholar
• Garza-Morales R, Gonzalez-Ramos R, Chiba A, et al. Temozolomide enhances triple-negative breast cancer virotherapy in vitro. Cancers (Basel). 2018;10(5):144.
   Web of Science ®Google Scholar
• Bai Y, Chen Y, Hong X, et al. Newcastle disease virus enhances the growth-inhibiting and proapoptotic effects of temozolomide on glioblastoma cells in vitro and in vivo. Sci Rep. 2018;8(1):11470.
   PubMed Web of Science ®Google Scholar
• Pisklakova A, McKenzie B, Zemp F, et al. M011L-deficient oncolytic myxoma virus induces apoptosis in brain tumor-initiating cells and enhances survival in a novel immunocompetent mouse model of glioblastoma. Neuro Oncol. 2016;18:1088–1098.
   PubMed Web of Science ®Google Scholar
• Ning J, Wakimoto H, Peters C, et al. Rad51 degradation: role in oncolytic virus-poly(ADP-Ribose) polymerase inhibitor combination therapy in glioblastoma. J Natl Cancer Inst. 2017;109(3):1–13.
   PubMedGoogle Scholar
• Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006;66(24):11851–11858.
   PubMed Web of Science ®Google Scholar
• Heo J, Breitbach CJ, Moon A, et al. Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy. Mol Ther. 2011;19(6):1170–1179.
   PubMed Web of Science ®Google Scholar
• Kim JH, Oh JY, Park BH, et al. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther. 2006;14(3):361–370.
   PubMed Web of Science ®Google Scholar
• Stiles BM, Adusumilli PS, Stanziale SF, et al. Estrogen enhances the efficacy of an oncolytic HSV-1 mutant in the treatment of estrogen receptor-positive breast cancer. Int J Oncol. 2006;28(6):1429–1439.
   PubMed Web of Science ®Google Scholar
• Cameron F, Whiteside G, Perry C. Ipilimumab: first global approval. Drugs. 2011;71(8):1093–1104.
   PubMed Web of Science ®Google Scholar
• Poole RM. Pembrolizumab: first global approval. Drugs. 2014;74(16):1973–1981.
   PubMed Web of Science ®Google Scholar
• Raedler LA. Opdivo (Nivolumab): second PD-1 inhibitor receives FDA approval for unresectable or metastatic melanoma. Am Health Drug Benefits. 2015;8(Spec Feature):180–183.
   PubMedGoogle Scholar
• Markham A, Duggan S. Cemiplimab: first global approval. Drugs. 2018;78(17):1841–1846.
   PubMed Web of Science ®Google Scholar
• Markham A. Atezolizumab: first global approval. Drugs. 2016;76(12):1227–1232.
   PubMed Web of Science ®Google Scholar
• Kim ES. Avelumab: first global approval. Drugs. 2017;77(8):929–937.
   PubMed Web of Science ®Google Scholar
• Syed YY. Durvalumab: first global approval. Drugs. 2017;77(12):1369–1376.
   PubMed Web of Science ®Google Scholar
• Lim M, Xia Y, Bettegowda C, et al. Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol. 2018;15(7):422–442.
   PubMed Web of Science ®Google Scholar
• Jackson CM, Choi J, Lim M. Mechanisms of immunotherapy resistance: lessons from glioblastoma. Nat Immunol. 2019;20(9):1100–1109.
   PubMed Web of Science ®Google Scholar
• Nakao S, Arai Y, Tasaki M, et al. Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade. Sci Transl Med. 2020;12(526):eaax7992.
   PubMed Web of Science ®Google Scholar
• Sivanandam V, LaRocca CJ, Chen NG, et al. Oncolytic viruses and immune checkpoint inhibition: the best of both worlds. Mol Ther Oncolytics. 2019;13:93–106.
   PubMed Web of Science ®Google Scholar
• Mahalingam D, Wilkinson GA, Eng KH, et al. Pembrolizumab in combination with the oncolytic virus Pelareorep and chemotherapy in patients with advanced pancreatic adenocarcinoma: a phase Ib study. Clin Cancer Res. 2020;26(1):71–81.
   PubMed Web of Science ®Google Scholar
• Karapanagiotou EM, Roulstone V, Twigger K, et al. Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin Cancer Res. 2012;18(7):2080–2089.
   PubMed Web of Science ®Google Scholar
• Harrington KJ, Hingorani M, Tanay MA, et al. Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin Cancer Res. 2010;16(15):4005–4015.
   PubMed Web of Science ®Google Scholar
• Opyrchal M, Aderca I, Galanis E. Phase I clinical trial of locoregional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomas. Methods Mol Biol. 2009;542:705–717.
   PubMedGoogle Scholar
• Schenk EL, Mandrekar SJ, Dy GK, et al. A randomized double-blind phase II study of the Seneca Valley Virus (NTX-010) versus Placebo for patients with extensive-stage SCLC (ES SCLC) who were stable or responding after at least four cycles of platinum-based chemotherapy: North Central Cancer Treatment Group (Alliance) N0923 study. J Thorac Oncol. 2020;15(1):110–119.
   PubMed Web of Science ®Google Scholar
• Moehler M, Heo J, Lee HC, et al. Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter phase IIb trial (TRAVERSE). Oncoimmunology. 2019;8(8):1615817.
   PubMed Web of Science ®Google Scholar
• Jonker DJ, Tang PA, Kennecke H, et al. A randomized phase II study of FOLFOX6/Bevacizumab with or without pelareorep in patients with metastatic colorectal cancer: IND.210, a Canadian cancer trials group trial. Clin Colorectal Cancer. 2018;17(3):231–239 e7.
   PubMed Web of Science ®Google Scholar
• Cheema TA, Wakimoto H, Fecci PE, et al. Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. Proc Natl Acad Sci U S A. 2013;110(29):12006–12011.
   PubMed Web of Science ®Google Scholar
• Xu B, et al. An oncolytic herpesvirus expressing E-cadherin improves survival in mouse models of glioblastoma. Nat Biotechnol. 2018;37:45–54.
   Google Scholar